drugset / Trial / NCT00092287
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to compare the efficacy and safety of lanreotide Autogel and Sandostatin LAR Depot, to see whether these two 28-day prolonged release formulations produce a similar clinical response in patients with carcinoid syndrome.
Timeline
- Start
- 2004-07
- Primary completion
- —
- Completion
- 2004-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanreotide | Other / unclassified | 90 mg | Subcutaneous |
| Subject | Lanreotide | Other / unclassified | 120 mg | Subcutaneous |
| Subject | Octreotide | Peptide | 20 mg | Intramuscular |
| Subject | Octreotide | Peptide | 30 mg | Intramuscular |